How does TB-500 work?

The proposed mechanism is tied to thymosin beta-4 biology. The source links the LKKTETQ region to G-actin binding, cytoskeletal remodeling, and migration of cells into damaged tissue. It also reports anti-inflammatory and pro-angiogenic findings in laboratory models. A key limitation is that a short synthetic fragment may not mirror all actions of the full thymosin beta-4 protein.

Is TB-500 FDA approved?

No. The supplied source lists TB-500 as not FDA approved and describes its current status as preclinical with no human clinical trials for the fragment. It also notes FDA Category 2 status with pending reclassification to Category 1 under an April 15, 2026 HHS announcement, remaining Category 2 until a formal FDA rule, with PCAC review dated July 23-24, 2026.

What typical dose is reported for TB-500?

The source gives community-reported dosing, not clinical guidance: 2-2.5 mg twice weekly during loading, then 2.5 mg once weekly for maintenance, with a listed loading range of 2-10 mg per week. It also lists subcutaneous or intramuscular injection and a frequency of 2x weekly for 4-6 weeks, then 1x weekly.

Regeneracja Przedkliniczne - tylko badania na zwierzętach

TB-500

Znany też jako: Thymosin Beta-4 fragment (LKKTETQ), Thymosin Beta-4, Fragment

W skrócie

Zbiór danych PeptiGuide · przegląd sie 2026

Czym jest

Synthetic thymosin beta-4 fragment researched for repair biology, with evidence still largely preclinical for TB-500 itself.

Status

Przedkliniczne

Poziom dowodów: badania na zwierzętach

Typowa dawka

2–2,5mg

Subcutaneous or intramuscular injection

Badany pod kątem

Muscle recovery, wound healing, injury rehabilitation

Postęp badań

PrePrzedkliniczne
IFaza I
IIFaza II
IIIFaza III
IVFaza IV
FDAZatwierdzone przez FDA

Przedkliniczne - Obiecujące wyniki na zwierzętach, ograniczone dane u ludzi

Użyj narzędzi

Prostym językiem

Synthetic peptide associated with the active region of thymosin beta-4; many products reproduce LKKTETQ, residues 17 to 23.
Researched for muscle recovery, wound healing, and injury rehabilitation.
Evidence level supplied as Animal Studies, mapped here to preclinical.
Source status: preclinical, no human clinical trials for the TB-500 fragment, and not FDA approved.
Community-reported typical dose: 2-2.5 mg twice weekly during loading, then 2.5 mg once weekly maintenance; administration listed as subcutaneous or intramuscular injection.

Jak prawdopodobnie działa

TB-500 is presented as a synthetic peptide based on the thymosin beta-4 active region. The supplied source identifies LKKTETQ, residues 17 to 23, as the short sequence commonly reproduced in TB-500 products and ties that region to G-actin binding. Through this actin-related pathway, thymosin beta-4 research connects cytoskeletal remodeling with cell migration into wound areas. The source also reports anti-inflammatory and pro-angiogenic activity in lab models. The main uncertainty is translational: evidence from full-length thymosin beta-4 does not prove that a 7-amino-acid fragment will reproduce the parent molecule's full biological profile.

Co pokazują badania

Na jakim etapie są badania

The supplied research summary places TB-500 mainly in a preclinical evidence category and says most of the stronger evidence concerns full-length thymosin beta-4 rather than the TB-500 fragment. It reports animal findings in wound, scar, tendon, skin, and cardiac injury models. For human data, the source discusses RegeneRx programs using thymosin beta-4 forms: RGN-259 eye drops in a placebo-controlled Phase 3 neurotrophic keratopathy study, where corneal healing was reported in 6 of 10 treated patients versus 1 of 8 on placebo, and RGN-352 injection, which reached Phase 2 in a cardiac program before a manufacturing hold. These programs are not presented as human efficacy trials of the 7-amino-acid TB-500 fragment. For TB-500 as a fragment, the source states there are no completed, published human efficacy trials for muscle or tendon repair and mentions a recently listed cardiovascular biomarker study as early-stage.

Co pokazują

✓ Badania na zwierzętach

Obiecujące wyniki na zwierzętach, ograniczone dane u ludzi

△ Ograniczenia

Dawki stosowane u zwierząt mogą nie przekładać się bezpośrednio na ludzi.

Podsumowanie: Preclinical - No human clinical trials. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026) Not FDA Approved

Typowe dawkowanie

SpołecznośćZbiór danych społeczności

2–2,5 mg

twice weekly (loading), then 2.5 mg once weekly (maintenance)

2 mgpełny obserwowany zakres10 mg

Community-reported schedule. Source describes a loading period intended to raise tissue levels, a maintenance period, and common stacking with BPC-157 for injury-recovery contexts; this is not a clinical recommendation.

Dawkowanie badawcze

Tylko zwierzętaTylko badania na zwierzętach - mogą nie przekładać się na ludzi

Dawki obserwowane w badaniach

2-2.5 mg twice weekly

Preclinical Research - Animal studies on Thymosin Beta-4 wound healing

Dawki stosowane u zwierząt mogą nie przekładać się bezpośrednio na ludzi.

Czas trwania: 4-6 weeks loading, then maintenance
Podanie: Subcutaneous or intramuscular injection

Timing i podanie

Najlepsza pora

Morning or evening

2-3 times per week

Zalecenia żywieniowe

With or without food

Dlaczego taki timing?

The source characterizes timing as flexible because TB-500 is described as having a long half-life; maintaining a consistent schedule is presented as more important than choosing a specific time of day.

Możliwe skutki uboczne

Nie każdy ich doświadcza. Indywidualne reakcje zależą od dawki, czasu trwania i czynników osobistych.

Generally well-tolerated in preclinical studies
Injection site reactions
Headache
Fatigue
Nausea
May trigger histamine release
Theoretical risk of facilitating tumor cell migration
Contraindicated with active cancer or cancer history
Limited long-term safety data
WADA prohibited at all times

Nie każdy doświadcza skutków ubocznych, a nasilenie może zależeć od kontekstu, czystości, drogi podania i indywidualnych czynników zdrowotnych.

Źródła

PubMed ClinicalTrials.gov FDA.gov

Najczęstsze pytania

TB-500 is described as a synthetic peptide modeled on the active region of thymosin beta-4. The source says many products center on LKKTETQ, residues 17 to 23, which is associated with actin binding and cell movement. Its research positioning is mainly around muscle recovery, wound healing, and injury rehabilitation, but the supplied evidence emphasizes that completed human trials for the TB-500 fragment itself are essentially absent; much of the human evidence discussed involves full-length thymosin beta-4.

Reported items in the source include general tolerability in preclinical studies, injection site reactions, headache, fatigue, and nausea. Additional cautions listed are possible histamine release in people with MCAS or histamine sensitivity, limited long-term safety data, a theoretical concern related to tumor cell migration because thymosin beta-4 is upregulated in metastatic cancers, a contraindication note for active cancer or cancer history, and WADA prohibition at all times on the 2025 list.

Sekwencja

Leu-Lys-Lys-Thr-Glu-Thr-Gln

Jeden otwarty zbiór danych

Każdy fakt na tej stronie - dawki, skutki uboczne, referencje - pochodzi z tego samego zbioru danych PeptiGuide, który zasila Tracker, Porównywarkę i Lab.

Przeglądaj zbiór danych

Zapisz na mojej liście Aktualizacje o TB‑500

Materiał edukacyjny, nie porada medyczna. Porozmawiaj z lekarzem, zanim podejmiesz działania.

Dyskusja społeczności

Komentarze są moderowane przed publikacją. Trzymajmy się dowodów.

TB-500

Prostym językiemProstym językiem

Jak prawdopodobnie działaJak prawdopodobnie działa

Co pokazują badaniaCo pokazują badania

Typowe dawkowanie

Dawkowanie badawcze

Timing i podanieTiming i podanie

Możliwe skutki uboczneMożliwe skutki uboczne

ŹródłaŹródła

Najczęstsze pytaniaNajczęstsze pytania

What does TB-500 do?